Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • Angiotensin II Mechanisms, Clinical Applications, and Resear

    2025-08-01

    Angiotensin II: Mechanisms, Clinical Applications, and Research Perspectives in Modern Pharmacotherapy
    Introduction [Related: rock inhibitor y 27632]
    Angiotensin II is a potent octapeptide hormone that plays a central role in the regulation of blood pressure, fluid, and electrolyte balance within the renin-angiotensin-aldosterone system (RAAS). As both an endogenous peptide and a pharmacological agent, angiotensin II has garnered significant attention for its vasoconstrictive properties and its ability to modulate cardiovascular and renal physiology. Recent advances have led to the development of synthetic angiotensin II formulations for clinical use, particularly in the management of vasodilatory shock refractory to conventional therapies (Khanna et al., 2017, NEJM). This paper provides a comprehensive review of angiotensin II, focusing on its mechanism of action, clinical value, challenges addressed, supporting literature, experimental data, usage guidelines, and future research directions.
    [Related: tsa stock] Mechanism of Action
    Angiotensin II is generated from angiotensin I through the action of angiotensin-converting enzyme (ACE). It exerts its physiological effects primarily via binding to angiotensin II type 1 receptors (AT1R) on vascular smooth muscle cells, leading to vasoconstriction and increased systemic vascular resistance. Additionally, angiotensin II stimulates aldosterone secretion from the adrenal cortex, promoting sodium and water retention, and thus increasing blood volume and pressure (Carey & Siragy, 2003, Hypertension). Beyond its classic roles, angiotensin II influences cellular proliferation, inflammation, and fibrosis, implicating it in the pathophysiology of hypertension, heart failure, and chronic kidney disease (Mehta & Griendling, 2007, Circ Res). [Related: a2585]
    Clinical Value and Applications
    The therapeutic application of synthetic angiotensin II has been most notably realized in the management of vasodilatory shock, particularly in cases unresponsive to high-dose catecholamines and vasopressin. In 2017, the U.S. Food and Drug Administration (FDA) approved intravenous angiotensin II (Giapreza®) for the treatment of septic or other distributive shock, marking a significant advancement in critical care pharmacotherapy (Khanna et al., 2017, NEJM). Angiotensin II offers a novel mechanism of action compared to traditional vasopressors, providing an alternative pathway for restoring vascular tone and perfusion in patients with refractory hypotension.
    Beyond shock, angiotensin II and its analogs are extensively utilized in preclinical research to model hypertension, cardiac remodeling, and renal injury, facilitating the development of antihypertensive agents and RAAS modulators (Crowley et al., 2006, Hypertension). Its role as a research tool extends to studies on vascular biology, inflammation, and metabolic disorders.
    Key Challenges and Pain Points Addressed
    Vasodilatory shock, particularly septic shock, is characterized by profound hypotension and inadequate tissue perfusion despite aggressive fluid resuscitation and high-dose vasopressor therapy. Conventional agents such as norepinephrine and vasopressin may fail to restore adequate blood pressure in a subset of patients, leading to high morbidity and mortality (Russell, 2011, NEJM). Angiotensin II addresses several critical challenges in this context:
    1. **Catecholamine-Resistant Shock:** Angiotensin II provides an alternative vasopressor mechanism, independent of adrenergic receptors, which is particularly valuable in patients with catecholamine-refractory shock.
    2. **Renal Perfusion:** By preferentially constricting efferent arterioles, angiotensin II may improve glomerular filtration pressure and renal function in shock states (Tumlin et al., 2018, Crit Care Med).
    3. **Reduced Vasopressor Requirements:** The addition of angiotensin II can reduce the need for high-dose catecholamines, potentially minimizing adverse effects such as arrhythmias and ischemia (Khanna et al., 2017, NEJM).
    4. **Pharmacological Research:** In experimental settings, angiotensin II enables the study of RAAS-mediated pathologies and the evaluation of novel therapeutic interventions.
    Literature Review
    A growing body of literature supports the clinical and experimental utility of angiotensin II. Key studies include:
    1. **Khanna et al. (2017, NEJM):** In the landmark ATHOS-3 trial, synthetic angiotensin II significantly increased mean arterial pressure in patients with vasodilatory shock who were receiving high-dose vasopressors. The study demonstrated a rapid and sustained pressor response, with a favorable safety profile.
    2. **Tumlin et al. (2018, Crit Care Med):** A post hoc analysis of ATHOS-3 data revealed that angiotensin II administration was associated with improved renal outcomes, including increased urine output and reduced incidence of renal replacement therapy.
    3. **Carey & Siragy (2003, Hypertension):** This review elucidates the molecular and physiological actions of angiotensin II, highlighting its role in blood pressure regulation and end-organ damage.
    4. **Mehta & Griendling (2007, Circ Res):** The authors discuss the pleiotropic effects of angiotensin II on vascular remodeling, inflammation, and oxidative stress, providing insight into its involvement in cardiovascular disease.
    5. **Crowley et al. (2006, Hypertension):** This experimental study demonstrates the utility of angiotensin II infusion in rodent models to induce hypertension and investigate the pathogenesis of hypertensive end-organ damage.
    6. **Bellomo et al. (2019, Intensive Care Med):** A systematic review and meta-analysis of angiotensin II in vasodilatory shock concluded that it effectively increases blood pressure and may reduce mortality in selected patient populations.
    7. **Wang et al. (2020, J Am Soc Nephrol):** This study explores the renal hemodynamic effects of angiotensin II in acute kidney injury, supporting its potential role in preserving renal function during shock.
    Experimental Data and Results
    The efficacy and safety of angiotensin II in clinical and preclinical settings have been substantiated by robust experimental data. In the ATHOS-3 trial (Khanna et al., 2017), 321 patients with vasodilatory shock were randomized to receive either intravenous angiotensin II or placebo, in addition to standard vasopressor therapy. The primary endpoint—achievement of a target mean arterial pressure (MAP) of ≥75 mmHg at 3 hours—was met in 69.9% of the angiotensin II group versus 23.4% of the placebo group (p<0.001). Secondary endpoints included reductions in norepinephrine requirements and trends toward improved survival, though the latter did not reach statistical significance.
    Adverse events were comparable between groups, with no significant increase in thromboembolic or ischemic complications. Notably, patients with acute kidney injury demonstrated improved renal function and decreased need for renal replacement therapy when treated with angiotensin II (Tumlin et al., 2018).
    In preclinical research, continuous angiotensin II infusion in rodents reliably induces hypertension, cardiac hypertrophy, and renal injury, providing a reproducible model for studying the pathophysiology of cardiovascular and renal diseases (Crowley et al., 2006). These models have been instrumental in evaluating the efficacy of RAAS inhibitors and elucidating downstream signaling pathways.
    Usage Guidelines and Best Practices
    The clinical use of synthetic angiotensin II is primarily indicated for the treatment of vasodilatory shock refractory to conventional vasopressors. Key usage guidelines include:
    - **Dosing:** The recommended starting dose is 20 ng/kg/min, titrated every 5 minutes as needed to achieve target MAP, up to a maximum of 80 ng/kg/min during the first 3 hours. Maintenance doses typically range from 1 to 40 ng/kg/min (Khanna et al., 2017).
    - **Administration:** Angiotensin II is administered as a continuous intravenous infusion, with close hemodynamic monitoring.
    - **Monitoring:** Blood pressure, heart rate, renal function, and signs of ischemia should be closely monitored. Dose adjustments should be made based on clinical response and adverse events.
    - **Combination Therapy:** Angiotensin II is used as an adjunct to standard vasopressors (e.g., norepinephrine, vasopressin) and should not replace first-line agents.
    - **Contraindications and Cautions:** Caution is advised in patients with a history of thromboembolic events, mesenteric ischemia, or known hypersensitivity to angiotensin II. Prophylactic anticoagulation may be considered in high-risk patients.
    In research applications, angiotensin II is typically administered via osmotic minipumps or intravenous infusion in animal models, with dosing regimens tailored to the experimental objectives.
    Future Research Directions
    Several avenues for future research on angiotensin II are currently being explored:
    1. **Expanded Clinical Indications:** Ongoing trials are investigating the utility of angiotensin II in other forms of shock (e.g., cardiogenic, postoperative) and in the management of acute kidney injury.
    2. **Biomarker-Guided Therapy:** Identification Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 61 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11466884